<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">lvrach</journal-id><journal-title-group><journal-title xml:lang="ru">Лечащий Врач</journal-title><trans-title-group xml:lang="en"><trans-title>Lechaschi Vrach</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-5175</issn><issn pub-type="epub">2687-1181</issn><publisher><publisher-name></publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.51793/OS.2023.26.8.006</article-id><article-id custom-type="elpub" pub-id-type="custom">lvrach-1101</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ГАСТРОЭНТЕРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>GASTROENTEROLOGY</subject></subj-group></article-categories><title-group><article-title>Фенотипы синдрома раздраженного кишечника и стратегии пациентоориентированной курации больного</article-title><trans-title-group xml:lang="en"><trans-title>Phenotypes of irritable bowel syndrome and strategies for patient-oriented curation of patient</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9370-4768</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гаус</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gaus</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гаус Ольга Владимировна, к.м.н., доцент кафедры факультетской терапии и гастроэнтерологии</p><p>644037, Омск, ул. Петра Некрасова, 5</p></bio><bio xml:lang="en"><p>Olga V. Gaus, MD, Associate Professor of the Department of Faculty Therapy and Gastroenterology</p><p> 5 Petr Nekrasov str., Omsk, 644037</p></bio><email xlink:type="simple">gaus_olga@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6581-7017</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ливзан</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Livzan</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ливзан Мария Анатольевна, член-корреспондент Российской академии наук, д.м.н., профессор, заведующая кафедрой факультетской терапии и гастроэнтерологии, ректор</p><p>Scopus Author ID: 24341682600</p><p>644037, Омск, ул. Петра Некрасова, 5</p></bio><bio xml:lang="en"><p>Maria A. Livzan, Corresponding Member of the Russian Academy of Sciences, Dr. of Sci. (Med.), Professor, Head of the Department of Faculty Therapy and Gastroenterology, Rector </p><p> 5 Petr Nekrasov str., Omsk, 644037</p></bio><email xlink:type="simple">lyalykova@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования Омский государственный медицинский университет Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal State Budgetary Educational Institution of Higher Education Omsk State Medical University of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>22</day><month>08</month><year>2023</year></pub-date><volume>0</volume><issue>7-8</issue><fpage>36</fpage><lpage>44</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гаус О.В., Ливзан М.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Гаус О.В., Ливзан М.А.</copyright-holder><copyright-holder xml:lang="en">Gaus O.V., Livzan M.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.lvrach.ru/jour/article/view/1101">https://journal.lvrach.ru/jour/article/view/1101</self-uri><abstract><sec><title>Цель работы</title><p>Цель работы. Предложить пациентоориентированный подход к курации больного с синдромом раздраженного кишечника на основе выделенных фенотипов заболевания.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. На основе комплексного анализа взаимодействия факторов генетики и эпигенетики выделены и представлены характеристики фенотипов синдрома раздраженного кишечника. Для каждого фенотипа разработаны и апробированы индивидуализированные схемы терапии заболевания. Для оценки эффективности предложенных пациентоориентированных подходов проведено открытое когортное проспективное рандомизированное исследование в параллельных группах.</p></sec><sec><title>Результаты</title><p>Результаты. При постинфекционном синдроме раздраженного кишечника пациентам рекомендовано назначение штамма Lactobacillus paracasei CNCMI-1572, а также коррекция пищевых привычек с ограничением соли и продуктов, содержащих лактозу. При фенотипе синдрома раздраженного кишечника с избыточной массой тела и ожирением пациентам предложено ограничение продуктов с высоким гликемическим индексом, дополнительное назначение адеметионина, а также синбиотика, содержащего инулин, штаммы Bifidobacterium lactis Bl-04, Lactobacillus acidophilus La-14, Lactobacillus rhamnosus Lr-32 и витамины группы В. При коморбидном фенотипе целесообразно назначение цитопротектора ребамипида. Дополнительно необходима коррекция рациона питания с исключением продуктов-триггеров. При эссенциальном фенотипе пациентам рекомендован прием пробиотического штамма Bifidobacterium longum 35624. Применение предложенных пациентоориентированных стратегий дополнительно к стандартной терапии позволило достичь более эффективного купирования клинических проявлений и уменьшения степени тяжести синдрома раздраженного кишечника, повышения душевого благополучия, а также сократить частоту рецидивов заболевания.</p></sec><sec><title>Заключение</title><p>Заключение. Предложенные пациентоориентированные подходы к курации больного с синдромом раздраженного кишечника на основе выделенных фенотипов заболевания могут рассматриваться в качестве одного из возможных способов повышения эффективности терапии заболевания.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective. To propose a patient-oriented approach to the management of a patient with irritable bowel syndrome based on the identified phenotypes of the disease.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Based on a comprehensive analysis of the interaction of genetic and epigenetic factors, the characteristics of the phenotypes of irritable bowel syndrome have been identified and presented. For each phenotype, individualized treatment regimens for the disease have been developed and tested. To evaluate the effectiveness of the proposed patient-oriented approaches, an open cohort, prospective, randomized study in parallel groups was conducted.</p></sec><sec><title>Results</title><p>Results. With post-infectious irritable bowel syndrome, patients are recommended to prescribe a strain of Lactobacillus paracasei CNCMI1572, as well as correction of eating habits with restriction of salt and products containing lactose. With the phenotype of irritable bowel syndrome with overweight and obesity, patients were offered the restriction of foods with a high glycemic index, the additional appointment of ademetionine, as well as a synbiotic containing inulin, strains of Bifidobacteriumlactis Bl-04, Lactobacillusacidophilus La-14, Lactobacillusrhamnosus Lr-32 and B vitamins In the comorbid phenotype, it is advisable to prescribe the cytoprotector rebamipide. Additionally, a correction of the diet is necessary with the exclusion of trigger foods. With the essential phenotype, patients are recommended to take the probiotic strain Bifidobacterium longum 35624. The use of the proposed patient-oriented strategies in addition to standard therapy made it possible to achieve more effective relief of clinical manifestations and reduce the severity of irritable bowel syndrome, improve mental well-being, and reduce the frequency of relapses of the disease.</p></sec><sec><title>Conclusion</title><p>Conclusion. The proposed patient-oriented approaches to the management of a patient with irritable bowel syndrome based on the identified disease phenotypes can be considered as one of the possible ways to improve the effectiveness of disease therapy.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>синдром раздраженного кишечника</kwd><kwd>фенотип</kwd><kwd>пациентоориентированный подход к курации</kwd><kwd>постинфекционный синдром раздраженного кишечника</kwd><kwd>коморбидность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>irritable bowel syndrome</kwd><kwd>phenotype</kwd><kwd>patient-centered approach to curation</kwd><kwd>postinfectious irritable bowel syndrome</kwd><kwd>comorbidity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Black C. J., Ford A. C. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat. Rev. Gastroenterol. Hepatol. 2020; 17 (8): 473-486. DOI: 10.1038/s41575-020-0286-8.</mixed-citation><mixed-citation xml:lang="en">Black C. J., Ford A. C. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat. Rev. Gastroenterol. Hepatol. 2020; 17 (8): 473-486. DOI: 10.1038/s41575-020-0286-8.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lacy B. E., Patel N. K. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J. Clin. Med. 2017; 6 (11): 99. DOI: 10.3390/jcm6110099.</mixed-citation><mixed-citation xml:lang="en">Lacy B. E., Patel N. K. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J. Clin. Med. 2017; 6 (11): 99. DOI: 10.3390/jcm6110099.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Flacco M. E., Manzoli L., De Giorgio R., et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. Eur. Rev. Med Pharmacol. Sci. 2019; 23 (7): 2986-3000. DOI: 10.26355/eurrev_201904_17580.</mixed-citation><mixed-citation xml:lang="en">Flacco M. E., Manzoli L., De Giorgio R., et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. Eur. Rev. Med Pharmacol. Sci. 2019; 23 (7): 2986-3000. DOI: 10.26355/ eurrev_201904_17580.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Nellesen D., Yee K., Chawla A., Lewis B. E., Carson R. T. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J. Manag. Care. Pharm. 2013; 19 (9): 755-764. DOI: 10.18553/jmcp.2013.19.9.755.</mixed-citation><mixed-citation xml:lang="en">Nellesen D., Yee K., Chawla A., Lewis B. E., Carson R. T. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J. Manag. Care. Pharm. 2013; 19 (9): 755-764. DOI: 10.18553/jmcp.2013.19.9.755.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang F., Xiang W., Li C. Y., Li S. C. Economic burden of irritable bowel syndrome in China. World. J. Gastroenterol. 2016; 22 (47): 10450-10460. DOI: 10.3748/wjg.v22.i47.10450.</mixed-citation><mixed-citation xml:lang="en">Zhang F., Xiang W., Li C. Y., Li S. C. Economic burden of irritable bowel syndrome in China. World. J. Gastroenterol. 2016; 22 (47): 10450-10460. DOI: 10.3748/wjg.v22.i47.10450.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В. Т., Маев И. В., Шелыгин Ю. А. и др. Диагностика и лечение синдрома раздраженного кишечника (Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России). Рос. жур. гастроэнтерол., гепатол., колопроктол. 2021; 31 (5): 74-95 DOI: 10.22416/1382-4376-2021-31-5-74-95.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V. T., Maev I. V., Shelygin Yu. A. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Ros. zhur. gastroenterol., gepatol., koloproktol. 2021; 31 (5): 74-95. DOI: 10.22416/1382-4376-2021-31-5-74-95. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">WHO Europe. CINDI Health Monitor: A Study of feasibility of a health behaviour monitoring survey across CINDI countries. Available at: http://www.euro.who.int/__data/assets/pdf_file/0017/240236/e79396.pdf (access date: 25 June 2023).</mixed-citation><mixed-citation xml:lang="en">WHO Europe. CINDI Health Monitor: A Study of feasibility of a health behaviour monitoring survey across CINDI countries. Available at: http://www.euro.who. int/__data/assets/pdf_file/0017/240236/e79396.pdf (access date: 25 June 2023).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ерофеев Ю. В., Болдырева М. С., Турчанинов Д. В. и др. Организация и методика проведения социологических исследований здоровья сельского населения для информационного обеспечения системы социально-гигиенического мониторинга: Метод. рекомендации. Омск: ФГУ ЦГСЭН Омской области, 2004.</mixed-citation><mixed-citation xml:lang="en">Erofeev Ju. V., Boldyreva M. S., Turchaninov D. V., et al. Organization and methods of conducting sociological studies of the health of the rural population for information support of the system of social and hygienic monitoring: Method. recommendations. Omsk: FGU CGSJeN Omsk region, 2004. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zigmond A. S., Snaith R. P. The hospital anxiety and depression scale // Acta. Psychiatr. Scand. 1983; 67 (6): 361-370. DOI: 10.1111/j.1600-0447.1983.tb09716.</mixed-citation><mixed-citation xml:lang="en">Zigmond A. S., Snaith R. P. The hospital anxiety and depression scale // Acta. Psychiatr. Scand. 1983; 67 (6): 361-370. DOI: 10.1111/j.1600-0447.1983.tb09716.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Labus J. S., Bolus R., Chang L., et al. The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale // Aliment. Pharmacol. Ther. 2004; 20 (1): 89-97. DOI: 10.1111/j.1365-2036.2004.02007.</mixed-citation><mixed-citation xml:lang="en">Labus J. S., Bolus R., Chang L., et al. The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale // Aliment. Pharmacol. Ther. 2004; 20 (1): 89-97. DOI: 10.1111/j.1365-2036.2004.02007.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Drossman D. A., Patrick D. L., Whitehead W. E., et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am. J. Gastroenterol. 2000; 95 (4): 999-1007. DOI: 10.1111/j.1572-0241.2000.01941.x.</mixed-citation><mixed-citation xml:lang="en">Drossman D. A., Patrick D. L., Whitehead W. E., et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am. J. Gastroenterol. 2000; 95 (4): 999-1007. DOI: 10.1111/j.1572-0241.2000.01941.x.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Гаус О. В., Ливзан М. А. Фенотипы синдрома раздраженного кишечника: ведущие факторы генетики и эпигенетики, механизмы формирования. Терапевтический архив. 2023; 95 (2): 164-172. DOI: 10.26442/00403660.2023.02.202111.</mixed-citation><mixed-citation xml:lang="en">Gaus O. V., Livzan M. A. Irritable bowel syndrome phenotypes: leading factors of genetics and epigenetics, mechanisms of formation. Ter. Arkh. 2023; 95 (2): 164-172. DOI: 10.26442/00403660.2023.02.202111. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Гаус О. В., Ливзан М. А. Генетические факторы и течение синдрома раздраженного кишечника: ассоциации и взаимосвязи. РМЖ. Медицинское обозрение. 2023; 7 (5): 237-248. DOI: 10.32364/2587-6821-2023-7-5-1.</mixed-citation><mixed-citation xml:lang="en">Gaus O. V., Livzan M. A. Genetic factors and the course of irritable bowel syndrome: associations and interactions. RMZh. Meditsinskoe obozrenie. 2023; 7 (5): 237-248. DOI: 10.32364/2587-6821-2023-7-5-1. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bengtsson M., Ohlsson B., Ulander K. Development and psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS). BMC Gastroenterol. 2007; 7: 16. DOI: 10.1186/1471-230X-7-16.</mixed-citation><mixed-citation xml:lang="en">Bengtsson M., Ohlsson B., Ulander K. Development and psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS). BMC Gastroenterol. 2007; 7: 16. DOI: 10.1186/1471-230X-7-16.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Francis C. Y., Morris J., Whorwell P. J. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997; 11 (2): 395-402. DOI: 10.1046/j.1365-2036.1997.142318000.x.</mixed-citation><mixed-citation xml:lang="en">Francis C. Y., Morris J., Whorwell P. J. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997; 11 (2): 395-402. DOI: 10.1046/j.1365-2036.1997.142318000.x.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Zakostelska Z., Kverka M., Klimesova K., et al. Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLoS One. 2011; 6 (11): e27961. DOI: 10.1371/journal.pone.0027961.</mixed-citation><mixed-citation xml:lang="en">Zakostelska Z., Kverka M., Klimesova K., et al. Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLoS One. 2011; 6 (11): e27961. DOI: 10.1371/journal.pone.0027961.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ferrario C., Taverniti V., Milani C., et al. Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults. J. Nutr. 2014; 144 (11): 1787-1796. DOI: 10.3945/jn.114.197723.</mixed-citation><mixed-citation xml:lang="en">Ferrario C., Taverniti V., Milani C., et al. Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults. J. Nutr. 2014; 144 (11): 1787-1796. DOI: 10.3945/jn.114.197723.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">D'Incà R., Barollo M., Scarpa M., et al. Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. Dig. Dis. Sci. 2011; 56 (4): 1178-1187. DOI: 10.1007/s10620-010-1384-1.</mixed-citation><mixed-citation xml:lang="en">D'Incà R., Barollo M., Scarpa M., et al. Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. Dig. Dis. Sci. 2011; 56 (4): 1178-1187. DOI: 10.1007/s10620-010-1384-1.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Cremon C., Guglielmetti S., Gargari G., et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United. European. Gastroenterol. J. 2018; 6(4): 604-613. DOI: 10.1177/2050640617736478.</mixed-citation><mixed-citation xml:lang="en">Cremon C., Guglielmetti S., Gargari G., et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United. European. Gastroenterol. J. 2018; 6(4): 604-613. DOI: 10.1177/2050640617736478.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Asadi A., Shadab Mehr N., Mohamadi M. H., et al. Obesity and gut-microbiotabrain axis: A narrative review. J. Clin. Lab. Anal. 2022; 36 (5): e24420. DOI: 10.1002/jcla.24420.</mixed-citation><mixed-citation xml:lang="en">Asadi A., Shadab Mehr N., Mohamadi M. H., et al. Obesity and gut-microbiotabrain axis: A narrative review. J. Clin. Lab. Anal. 2022; 36 (5): e24420. DOI: 10.1002/jcla.24420.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Geurts L., Neyrinck A. M., Delzenne N. M., et al. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Benef Microbes. 2014; 5 (1): 3-17. DOI: 10.3920/BM2012.0065.</mixed-citation><mixed-citation xml:lang="en">Geurts L., Neyrinck A. M., Delzenne N. M., et al. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Benef Microbes. 2014; 5 (1): 3-17. DOI: 10.3920/BM2012.0065.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Torres-Fuentes C., Schellekens H., Dinan T. G., Cryan J. F. A natural solution for obesity: bioactives for the prevention and treatment of weight gain. A review. Nutr. Neurosci. 2015; 18 (2): 49-65. DOI: 10.1179/1476830513Y.0000000099.</mixed-citation><mixed-citation xml:lang="en">Torres-Fuentes C., Schellekens H., Dinan T. G., Cryan J. F. A natural solution for obesity: bioactives for the prevention and treatment of weight gain. A review. Nutr. Neurosci. 2015; 18 (2): 49-65. DOI: 10.1179/1476830513Y.0000000099.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Popkin B. M., Gordon-Larsen P. The nutrition transition: worldwide obesity dynamics and their determinants. Int. J. Obes. Relat. Metab. Disord. 2004; 28 Suppl 3: S2-S9. DOI: 10.1038/sj.ijo.0802804.</mixed-citation><mixed-citation xml:lang="en">Popkin B. M., Gordon-Larsen P. The nutrition transition: worldwide obesity dynamics and their determinants. Int. J. Obes. Relat. Metab. Disord. 2004; 28 Suppl 3: S2-S9. DOI: 10.1038/sj.ijo.0802804.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Natividad J. M., Lamas B., Pham H. P., et al. Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice. Nat. Commun. 2018; 9(1): 2802. DOI: 10.1038/s41467-018-05249-7.</mixed-citation><mixed-citation xml:lang="en">Natividad J. M., Lamas B., Pham H. P., et al. Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice. Nat. Commun. 2018; 9(1): 2802. DOI: 10.1038/s41467-018-05249-7.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Vijayvargiya P., Busciglio I., Burton D., et al. Bile acid deficiency in a subgroup of patients with irritable bowel syndrome with constipation based on biomarkers in serum and fecal samples. Clin. Gastroenterol. Hepatol. 2018; 16 (4): 522-527. DOI: 10.1016/j.cgh.2017.06.039.</mixed-citation><mixed-citation xml:lang="en">Vijayvargiya P., Busciglio I., Burton D., et al. Bile acid deficiency in a subgroup of patients with irritable bowel syndrome with constipation based on biomarkers in serum and fecal samples. Clin. Gastroenterol. Hepatol. 2018; 16 (4): 522-527. DOI: 10.1016/j.cgh.2017.06.039.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Wilson A. S-Adenosyl Methionine (SAMe) for Depression in Adults. Issues. Ment. Health. Nurs. 2019; 40 (8): 725-726. DOI: 10.1080/01612840.2017.1392161.</mixed-citation><mixed-citation xml:lang="en">Wilson A. S-Adenosyl Methionine (SAMe) for Depression in Adults. Issues. Ment. Health. Nurs. 2019; 40 (8): 725-726. DOI: 10.1080/01612840.2017.1392161.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Singh R., Zogg H., Ghoshal U. C., Ro S. Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders. Front. Pharmacol. 2022; 13: 808195. DOI: 10.3389/fphar.2022.808195.</mixed-citation><mixed-citation xml:lang="en">Singh R., Zogg H., Ghoshal U. C., Ro S. Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders. Front. Pharmacol. 2022; 13: 808195. DOI: 10.3389/fphar.2022.808195.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Lee J. S., Jeon S. W., Lee H. S., et al. Rebamipide for the Improvement of Gastric Atrophy and Intestinal Metaplasia: A Prospective, Randomized, Pilot Study. Dig. Dis. Sci. 2022; 67 (6): 2395-2402. DOI: 10.1007/s10620-021-07038-7.</mixed-citation><mixed-citation xml:lang="en">Lee J. S., Jeon S. W., Lee H. S., et al. Rebamipide for the Improvement of Gastric Atrophy and Intestinal Metaplasia: A Prospective, Randomized, Pilot Study. Dig. Dis. Sci. 2022; 67 (6): 2395-2402. DOI: 10.1007/s10620-021-07038-7.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Jaafar M. H., Safi S. Z., Tan M. P., et al. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig. Dis Sci. 2018; 63 (5): 1250-1260. DOI: 10.1007/s10620-017-4871-9.</mixed-citation><mixed-citation xml:lang="en">Jaafar M. H., Safi S. Z., Tan M. P., et al. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig. Dis Sci. 2018; 63 (5): 1250-1260. DOI: 10.1007/s10620-017-4871-9.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">O'Mahony L., McCarthy J., Kelly P., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005; 128 (3): 541-551. DOI: 10.1053/j.gastro.2004.11.050.</mixed-citation><mixed-citation xml:lang="en">O'Mahony L., McCarthy J., Kelly P., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005; 128 (3): 541-551. DOI: 10.1053/j.gastro.2004.11.050.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
